Myriad Genetics

Myriad Genetics is a molecular diagnostics company focused on the development and marketing of gene sequencing, personalized medicine tests, and prognostic medical tests in the United States and internationally. It aims to become a trusted research provider, transforming the lives of patients worldwide through pioneering molecular diagnostic technologies and their commercialization to determine disease risk, accurately diagnose diseases, assess the risk of disease progression, and guide treatment decisions across six major medical specialties. Molecular diagnostics can significantly improve patient care and reduce healthcare costs. Myriad focuses on three strategic priorities: maintaining leadership in the expanding hereditary cancer market, diversifying its product portfolio by launching new products, and increasing revenue contributions from international markets. Myriad revolutionizes patient care by discovering, developing, and marketing transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Since 1991, Myriad has invested heavily in educating patients and healthcare professionals about the role of genes and proteins in disease. Thousands of patients have benefited from Myriad's tests, which help healthcare professionals better manage and tailor medical services. By introducing new molecular diagnostic and companion diagnostic tests for an increasing number of diseases, Myriad is expanding its reach and increasing its impact on patient care.